Atezolizumab/Bevacizumab Moves Forward in Metastatic Renal Cell Carcinoma
The combination of atezolizumab plus bevacizumab showed promising results as first-line treatment of patients with metastatic renal cell...
Pediatric Cancer Pain May Be Misunderstood and Largely Undertreated
Cancer pain in children poses certain unique challenges. Over the past decade, insightful research into pediatric cancer pain has focused on...
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Metastatic Brain Disease
In the phase III NCCTG N107C/CEC.3 trial, stereotactic radiosurgery to the surgical cavity reduced cognitive deterioration and was associated with...
More Top Stories
Dacomitinib Outperforms Gefitinib in EGFR-Positive NSCLC
DACOMITINIB, a second-generation epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitor, outperformed gefitinib (Iressa) as first-line treatment for EGFR-positive advanced non–small cell lung cancer (NSCLC) in the phase III ARCHER 1050 study.1 Dacomitinib improved...
Addition of Cetuximab to Concurrent Chemoradiation in Esophageal Cancer
The phase III NRG Oncology RTOG 0436 trial has shown no survival benefit of adding cetuximab (Erbitux) to paclitaxel/cisplatin and radiation therapy in patients with esophageal cancer treated without surgery. These results were reported by Suntharalingam et al in JAMA Oncology. Study Details In...
World Health Assembly’s New Cancer Resolution Reflects New Realities
The World Health Assembly (WHA)—the decision-making body of the World Health Organization (WHO)—adopted a long-expected cancer resolution at its 2017 meeting, the body’s first resolution on cancer in 12 years and the first to emphasize, among other issues, the accessibility and affordability of...
Encouraging Results With Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
AN EFFECTIVE antitumor immune response relies on cytotoxic T cells that are activated and able to target the malignant clone. As T cells become activated, they upregulate suppressive receptors including programmed cell death protein 1 (PD-1). Upregulation of inhibitory signals is important to...
ASCO Offers Path to Addressing Affordability of Cancer Drugs in New Position Statement
Today, ASCO issued a position statement aimed at contributing to the national dialogue on rising cancer drug prices. The statement, which asserts that any solutions must also preserve patients' access to care and foster innovation, analyzes a wide array of options and recommends that a panel of...
Angela Alistar, MD, Joins Atlantic Health System Cancer Care
Gastrointestinal cancer researcher Angela Alistar, MD, has joined Atlantic Health System Cancer Care as Medical Director of GI Medical Oncology at Morristown Medical Center. Dr. Alistar is a board-certified medical oncologist who specializes in translational research. She comes to Atlantic...
FDA Approves Three-Drug Combination Tablet for Hepatitis C
On July 18, the U.S. Food and Drug Administration (FDA) approved a combination tablet (Vosevi) to treat adults with chronic hepatitis C virus genotypes 1–6 without cirrhosis or with mild cirrhosis. This fixed-dose, combination tablet contains two previously approved drugs—sofosbuvir and ...